The Adenosine Receptor A2a pipeline drugs market research report outlays comprehensive information on the Adenosine Receptor A2a targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Adenosine Receptor A2a pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Genetic Disorders, and Infectious Disease which include the indications Solid Tumor, Unspecified Cancer, Parkinson’s Disease, Alzheimer’s Disease, Fragile X Syndrome, Spinocerebellar Ataxia (SCA), and Sepsis. It also reviews key players involved in Adenosine Receptor A2a targeted therapeutics development with respective active and dormant or discontinued products.
The Adenosine Receptor A2a pipeline targets constitutes close to 46 molecules. Out of which, approximately 41 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 7, 3, 1, 23, and 6 respectively. Similarly, the universities portfolio in IND/ CTA Filed, Preclinical, and Discovery comprises 1, 2, and 2 molecule.
Adenosine Receptor A2a overview
The adenosine A2A receptor (ADORA2A) is a G protein-coupled receptor (GPCR) that binds to adenosine, a neuromodulator that plays a role in many physiological functions, including sleep, pain, and cognition. A2A receptors are found throughout the body, but they are particularly abundant in the brain, where they are involved in the regulation of dopamine release.
For a complete picture of Adenosine Receptor A2a’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
